Bristol Myers Squibb's RYZ101 Hits Primary Endpoint in Phase 3 GEP-NET Trial
Event summary
- Bristol Myers Squibb's RYZ101 (225Ac-DOTATATE) met primary endpoint of progression-free survival in Phase 3 ACTION-1 trial for GEP-NETs.
- Interim analysis showed statistically significant and clinically meaningful improvement in progression-free survival.
- RYZ101 is the first alpha-isotope based targeted radiopharmaceutical therapy to show Phase 3 results in any indication.
- FDA granted Orphan Drug Designation for RYZ101 in August 2026.
- Detailed results expected to be presented at a future medical meeting.
The big picture
Bristol Myers Squibb's positive Phase 3 results for RYZ101 mark a significant milestone in the radiopharmaceutical space, particularly for patients with advanced GEP-NETs who have limited treatment options after Lu177 therapy. The success of RYZ101 underscores the growing importance of targeted alpha-emitting radiopharmaceuticals in oncology, a trend that could reshape treatment paradigms for rare and refractory cancers. The strategic integration of RayzeBio's capabilities into Bristol Myers Squibb's portfolio highlights the company's commitment to advancing innovative therapies in this niche but high-unmet-need area.
What we're watching
- Regulatory Pathway
- Whether the FDA will expedite review given the Orphan Drug Designation and positive Phase 3 results.
- Commercial Potential
- The pace at which RYZ101 can capture market share in the GEP-NET space post-Lu177 therapy.
- Pipeline Expansion
- How these results will impact the development of RayzeBio's broader radiopharmaceutical pipeline.
